WEST LAFAYETTE, Ind. — An experimental drug has shown promise as a potential therapy for spinal cord injuries in animal studies. The compound, 4-aminopyridine-3-methanol, works in a similar way as a ...

Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion . JCO 22 , 1553 ...

Acorda Therapeutics Announces Acquisition of Aminopyridine and Pre-Clinical Assets from Neurorecovery Monday February 4 HAWTHORNE, N.Y. -- Acorda Therapeutics today announced the acquisition of ...